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Introduction
　Cystoid macular edema （CME） was reported as Irvine-Gass syndrome in 1969 1）. 
Implanting an ultraviolet （UV）-ltering intraocular lens （UV-ltering IOL） instead of the 
previously used UV-transmitting IOL reduced the incidence of CME after cataract surgery 2）; 
however, this solution is not completely effective and the problem of CME remains 3-5）. 
Even after small-incision cataract surgery, the incidence of angiographic macular edema 
（ME） with no visual impairment was recently reported at 10-30% of patients 6）.
　In 1994, a blue light and ultraviolet cut-off ltering intraocular lens （blue-ltering IOL） 
was developed to prevent cyanopsia after cataract surgery 8）.  Basic studies of retinal pig-
ment epithelial cells 9） and animal experiments 10, 11） demonstrated that such IOLs had a 
protective effect on the retina.  A blue-filtering IOL might therefore also decrease the 
incidence of CME compared with the UV-ltering IOL, and this hypothesis was supported 
by a retrospective clinical study by Miyake et al 7） showing prevention of CME using the 
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blue-ltering IOL.  Herein, we report a prospective clinical study comparing the effects of 
a blue-ltering IOL versus a UV-ltering IOL on ME incidence 3 and 12 months after 
implantation.
Patients and Methods
　Patients were recruited at the Showa University Hospital （Tokyo, Japan） from February 
2003 to March 2004.  Fifty patients were enrolled in the study.  The patients had age-
related cataracts and were all eligible for IOL implantation.  Informed consent was obtained 
from all patients and the study was approved by the Showa University Institutional Review 
board.
　Enrolled patients ranged in age from 50 to 80 years and the range of axial length was 
24 ± 2 mm.  Patients were excluded if they had undergone an intraocular operation or 
had hypertensive retinopathy, diabetic retinopathy, age-related macular degeneration, or no 
observable fundus.  Any patients receiving treatment for systemic disease with macular lesion 
were also excluded.  Patients were randomly assigned to receive a blue-ltering IOL （ENV-
13, Menicon Co. Ltd., Nagoya, Japan） or a UV-ltering IOL （ES-13, Menicon）.  Both lens 
types were assigned code numbers by a person who did not take part in this study.
　The two different IOL are made of poly （methyl methacrylate）, and both have a diame-
ter of 5.5 mm, a sharp edge, and a loop angle of 10 degrees （wing type）.  The blue-ltering 
IOL contains UV absorber of the benzotriazol type and azo dyes, and the UV-ltering IOL 
contains UV absorber of the benzotriazol type.  The transmittance of the blue-ltering IOL 
in water is 64% at 430 nm, 76% at 450 nm, 87% at 480 nm, and 93% at 520 nm, while the 
transmittance of the UV-ltering IOL is 94% at 430 nm and 99% at wavelengths longer 
than 450 nm.
　The cataract surgeries were carried out by two surgeons.  During the operation, the 
patient’s eyes were protected from the surgical microscope illumination light by blue and 
UV lters.  Two hours before surgery, the patients received 5% phenylephrine （Santen Phar-
maceutical Co. Ltd., Osaka, Japan）, 0.5% tropicamide （Santen Pharmaceutical）, and 0.1% 
sodium diclofenac （Wakamoto Pharmaceutical Co. Ltd., Tokyo, Japan） by topical instillation 
every 30 minutes.  Just prior to surgery, subtenon anesthesia was given using 1 ml of 2% 
lidocaine.  The cataract was removed by phacoemulsication and aspiration, and then the 
blue-ltering and UV-ltering IOLs were tted randomly.  All patients received the following 
postoperative treatment : a subconjunctival injection of 0.8 mg betamethasone （Shionogi & 
Co. Ltd., Osaka, Japan） and antibiotics.  Topical application of 0.1% betamethasone phos-
phate （Shionogi & Co.）, 0.1% diclofenac sodium, and antibiotics were started on the rst 
postoperative day and continued at four times a day for six weeks.
　After cataract surgery, the patients were examined using a slit-lamp biomicroscope and 
funduscope.  Measurements of intraocular pressure, Snellen visual acuity, and refraction were 
carried out at 1 week and 3, 6, and 12 months postoperatively.  At 3 and 12 months after 
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the surgery, macular leakage was determined by uorescence angiography （FA）.  Following 
intravenous injection of 5 ml of uorescein-mono-glucuronide （Alcon, Fort Worth, TX, USA）, 
FA photographs were taken 10 and 20 minutes after the injection using a fundus camera 
（VX-10, Kowa Co., Tokyo, Japan） and digitally adjusted on a monitor using processing 
software.  Macular edema （ME） was assessed based on the incidence of macular leakage by 
ophthalmologists blinded to the type of IOL （Fig. 1）.
　Macula thickness was determined by optical coherence tomography （OCT, OCT3000, 
Carl Zeiss Meditec, Jena, Germany） and the value was corrected based on axial length 
and refraction.  Statistical analysis was performed using the Mann-Whitney U-test, and the 
Mantel-Haenszel chi square test was used to compare the recovery rates between the blue-
ltering and UV-ltering IOL groups.
Results
　A total of 50 patients were evaluated in this study.  Twenty-four eyes received a blue-
ltering IOL and 26 eyes received a UV-ltering IOL.  Five subjects （3 in the blue- and 
2 in the UV-ltering IOL group） withdrew from the study between 3 and 12 months after 
implantation for personal reasons.  The number of eyes evaluated to completion of the 
study was 45.  All patients were Japanese and the mean age was 71.4 years （range 56 to 80 
years）.  There was no signicant difference between the groups with regard to patient age : 
71.4 ± 6.8 years old in the blue- and 71.5±6.7 years old in the UV-ltering IOL group ; 
gender （male/female）: 6/15 in the blue- and 5/19 in the UV-filtering IOL group ; axial 
length : 23.8 ± 0.7 mm in the blue- and 23.6±0.8 mm in the UV-ltering IOL group.
　The cataract surgery was uneventful in all cases and the surgical time was less than 20 
minutes : 16.5 ± 2.4 minutes in the blue- and 15.8±3.4 minutes in the UV-filtering IOL 
group （Table 1）.  In all cases, the posterior capsules were left without rupture.  No intra-
Fig. 1.  Representative FA and OCT imaging of eyes with macular leakage. 
FA : fluorescence angiography fundus photograph showing macular leakage, 
OCT : optical coherence tomography showing macula thickness.
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operative complications occurred in the current series.  The implanted IOL refractions were 
22.4 ± 2.2 D in the blue-ltering IOL group and 22.3±2.0 D in the UV-ltering IOL group.
　Postoperative inflammation in the anterior segment was observed in patients without 
intraoperative complications or signs of infections, but examination of the fundus using a 
slit lamp and a funduscope revealed no abnormal ndings in any patients, including macular 
lesions.  The inammation was successfully treated within a week by topical administration 
of 0.1% betamethasone phosphate, 0.1% diclofenac sodium, and antibiotics.  During the 
study period, no patients developed after-cataracts and therefore did not require follow-up 
Nd-YAG laser treatment.  Visual acuity in all the patients was above 14/20 and no signi-
cant differences were observed at 3 and 12 months after IOL implantation between the 
groups （Table 2）.
　In the blue-ltering IOL group, FA results 3 months after IOL implantation were as fol-
lows : without ME in 16 eyes, with ME in 5 eyes.  At 12 months after implantation, only 
Table 1.  Baseline Data
Blue-ltering IOL
n＝ 21
UV-ltering IOL
n＝ 24
P value
Age （years） 71.4 ± 6.8 71.5 ± 6.7 0.95
Gender （male/female） 6/15 5/19 0.56
Axial length （mm） 23.8 ± 0.7 23.6 ± 0.8 0.38
IOL power （D） 22.4 ± 2.2 22.3 ± 2.0 0.83
Surgical time （minutes） 16.5 ± 2.4 15.8 ± 3.4 0.41
Data represent mean ± SD. P values are Blue- vs UV-ltering IOL.
Table 2.   Distribution of visual acuity at 3 and 12 months after IOL 
implantation
Post implantation visual acuity Blue-ltering IOL UV-ltering IOL
 3 months n＝ 21 n＝ 24
14/20 4 1
16/20 5 3
18/20 3 3
20/20 3 8
24/20 6 9
12 months n＝ 21 n＝ 24
16/20 3 2
18/20 4 3
20/20 7 6
24/20 6 13
30/20 1 0
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one eye still showed ME, while all others had improved.  In all cases, leakage was from 
perifoveal microvascular structures, and it was not caused by a window defect.  No CME 
was observed in any of the patients who received a blue-ltering IOL.  The incidence of 
macular leakage decreased from 24% （5/21） at 3 months to 5% （1/21） at 12 months in the 
blue-ltering IOL group.  In the UV-ltering IOL group, FA results 3 months after IOL 
implantation showed 18 eyes without ME, and 6 eyes with ME.  At 12 months, 19 eyes 
were without ME, while edema remained in 5 eyes.  After UV-ltering IOL implantation, 
the incidence of macular leakage decreased only slightly from 25% （6/24） at 3 months to 
21% （5/24） at 12 months.  Thus, at 12 months after implantation, the recovery rate in the 
blue-ltering IOL group was signicantly higher than that in the UV-ltering IOL group 
（Table 3, P = 0.046）.  OCT ndings at 3 and 12 months after IOL implantation are listed 
in Table 4, and Fig.1 shows a representative OCT image showing macular leakage.  The 
foveal thickness decreased from 175±40μm （n = 21） at 3 months to 166±38μm （n = 
21） at 12 months after blue-ltering IOL implantation （P = 0.43）.
Discussion
　In this study, the incidence of ME was decreased by blue-ltering （visible light transmit-
ting without blue light） IOL implantation, compared to UV-ltering （visible light transmit-
Table 3.   Angiographic macular edema assessment at 3 and 12 months after blue- or 
UV-ltering IOL implantation
Post implantation Distribution of 
Angiographic ME
Blue-ltering IOL UV-ltering IOL
3 months n＝ 21 n＝ 24
without 16 18
with  5  6
Incidence of macular leakage （%） 5/21 （24%） 6/24 （25%）
12 months n＝ 21 n＝ 24
without 20 19
with  1  5
Incidence of macular leakage （%） 1/21 （ 5%） 5/24 （21%）
At 12 months, the recovery rate in the blue-ltering IOL group was signicantly higher 
than that in the UV-ltering IOL group （P＝ 0.046）.
Table 4.  OCT at 3 and 12 months after IOL implantation
Post implantation Blue-ltering IOL
（μm） n＝ 21
UV-ltering IOL
（μm） n＝ 24
P values
 3 months 175 ± 40 174 ± 29 0.45
12 months 166 ± 38 172 ± 24 0.26
Data represent mean ± SD. P values are Blue- vs UV-ltering IOL.
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ting） IOL implantation 12 months after surgery, despite the same incidence of macular 
leakage at 3 months.  We found that all patients who were free of ME at 3 months after 
surgery had not developed any leakage at 12 months.  Thus, the recovery rate in the blue-
ltering IOL group was higher than that in the UV-ltering IOL group.
　It has been reported that the cause of CME is multifactorial including the release of bio-
active substances such as prostaglandins, cytokines, and growth factors following cataract sur-
gery 12-14）. We therefore proposed that the onset of CME after cataract surgery may relate to 
oxidative stress in the retina due to the following : 1） the retina absorbs short wavelength 
（UV and blue） light leading to a photochemical reaction that generates reactive oxygen 
species （ROS）15）, and resultant oxidative stress ; 2） ROS activate transcription factors, such 
as nuclear factor kappa B16） and mitogen-activated protein kinase （MAPK）, and thereby 
increase cycloxygenase-2 activity ; 3） these transcription factors then upregulate the cytokines, 
vascular endothelial growth factor （VEGF）17） and interleukin-1 beta （IL-1 beta）18）, as well 
as prostaglandins in the retina ; and then, 4） these biologically active compounds disrupt the 
tight junctions by inhibiting de novo synthesis of the required component proteins, leading 
to macular edema 19, 20） Gass et al 1） showed regression of edema in 50% of CME patients 6 
months after cataract surgery and in 20% of patients between 1 and 3 years, with 30% of 
patients showing no improvement in 3 or more years.  In the present study, the incidence 
of macular leakage was almost the same at 3 months in both groups, but the recovery rate 
in the UV-ltering IOL group was lower than that in the blue-ltering IOL at 12 months 
after implantation.  The action spectrum of retinal phototoxicity increases logarithmically as 
the wavelength of irradiation decreases 21）, thus exposure to short-wavelength （UV and blue） 
light induces severe oxidative stress in the retina.  In the UV-ltering IOL group, the retina 
had therefore received blue light and oxidative stress, which could underlie the low recovery 
rate observed in the UV-ltering IOL group.  Based on these results, a blue-ltering IOL 
may contribute to improving ME, but not to preventing onset.  The energy of a surgical 
microscope and the duration of retinal illumination time could activate the ME onset, and 
future studies should investigate this effect.
　This study evaluated the incidence of angiographic ME after cataract surgery as the 
endpoint of our comparison.  In the retina, there are several chromophores 22, 23） that absorb 
blue light and generate ROS, which are immediately scavenged by antioxidants.  However, 
the amount of antioxidants decreases with aging and inammation 24）, and thus ROS might 
easily attack the retinal cells during and following cataract surgery 25）.  We recommend that 
a blue-ltering IOL implanted to prevent oxidative stress in the retina will be more effective 
in resolving ME after cataract surgery than a UV-ltering IOL.
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